Immuron (ASX:IMC) reported a period of robust organic growth, headlined by a double-digit increase in global sales for the third quarter of fiscal year 2026.
The biopharmaceutical company, which specialises in the over-the-counter immune supplement Travelan, announced that global Q3 sales reached $1.5 million, marking a 16% rise over the prior comparative period.
The performance brings the year-to-date total to $5.7 million as of March, a 7% increase year-on-year.
The company’s domestic market remains its primary engine for revenue, with Australian Q3 sales climbing 15% to $0.9 million.
The Australian YTD figures show a 14% increase, totalling $4.2 million.
While the North American markets showed more varied results, there were significant strategic breakthroughs.
In Canada, Q3 sales surged by over 100% compared to the pcp, bolstered by an 82% increase over the previous quarter following initial sales to Jean Coutu in Quebec.
Despite these recent gains, the Canadian YTD remains down 65%, reflecting a transitional period for the region.
In the United States, sales remained stable with a modest 1% Q3 increase to $0.5 million, though the YTD trajectory remains positive with a 10% overall improvement to $1.3 million.
The unaudited results highlight a steady upward trend in the adoption of Immuron’s gastrointestinal health products.
At the time of reporting, Immuron’s share price was $0.035.